Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Inclusion Criteria:

Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as:
Pathologically-proven diagnosis of prostate adenocarcinoma
PSA 10-20ng/mL or
Gleason =7 or
Clinical stage T2b/c
Clinical stage T2b/c Additionally, patients will be required to meet the following criteria
Age ≥18
KPS≥70
Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician.
International Prostate Symptom Score ≤15

Exclusion Criteria:

Prior prostate surgery (including TURP)
Prior history of chronic prostatitis or urethral stricture
Inflammatory bowel disease
Prior history of pelvic radiotherapy
Unable to give informed consent
Metastatic disease.